Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Jubilant Pharmova Limited (JUBLPHARMA.NS)
INR1,028.40
+53.95 (+5.54%)
IN NSE Healthcare Drug Manufacturers - Specialty & Generic
Address
1A, Sector 16A 201301
Noida, IN
Noida, IN
CEO
Priyavrat Bhartia
Website
jubilantpharmova.com
IPO
2002-07-01
ISIN INE700A01033
Also trades on
Bombay Stock Exchange · JUBLPHARMA.BO (INR)
National Stock Exchange of India · JUBLPHARMA.NS (INR)
Description
Jubilant Pharmova Limited functions as a comprehensive pharmaceutical enterprise with a global footprint, structured into three primary divisions: Pharmaceuticals; Contract Research & Development Services; and Proprietary Novel Drugs. The Pharmaceuticals segment is involved in a range of activities, including the production and distribution of allergy treatments, outsourced manufacturing of both sterile injectable and non-sterile medications, the creation of active pharmaceutical ingredients (APIs), and solid dose formulations. This division also markets radiopharmaceuticals through a network of 48 specialized pharmacies located across the United States. Its Contract Research & Development Services arm offers collaborative scientific investigation to pioneering pharmaceutical companies. Furthermore, the Proprietary Novel Drugs segment focuses on developing innovative therapies for conditions such as cancer and autoimmune diseases. Established in 1978 and headquartered in Noida, India, the company was formerly named Jubilant Life Sciences Limited before adopting its current designation, Jubilant Pharmova Limited, in February 2021.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
INR1,028.40
+53.95 (+5.54%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
125.6K
Beta
0.51
Float Shares
63.53M
Free Float %
40.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.19% | -3.60% | +4.21% | +11.61% | -10.86% | -8.21% | -12.15% | +171.48% | +9.83% | +184.66% | +1,766.26% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
1,028.40
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
1.96
Grey zone
Piotroski F-Score
4 / 9
Average
MOAT Score
7 / 10
Strong MOAT
Composite Rating
B-
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+14.5% ★ Q1'26: +18.7% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-52.5% Q1'26: -22.4% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+6.4% Q1'26: -16.2% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+9.9% Q1'26: +9.7% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+5.6% Q1'26: +6.4% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.0% Q1'26: +0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×2.87× Q1'26: 2.66× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 2 Rev. Ana. 2 EPS Ana. |
Mar 2027 2 Rev. Ana. 2 EPS Ana. |
Mar 2028 2 Rev. Ana. 2 EPS Ana. |
Mar 2029 1 Rev. Ana. 1 EPS Ana. |
Mar 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
58.26B
est: 58.78B (-0.9%)
|
57.49B
est: 57.99B (-0.9%)
|
58.61B
est: 58.76B (-0.3%)
|
75.18B
est: 73.53B (+2.2%)
|
91.11B
est: 90.77B (+0.4%)
|
59.76B
est: 90.48B (-34.0%)
|
60.99B
est: 77.58B (-21.4%)
|
61.30B
est: 59.89B (+2.3%)
|
62.82B
est: 61.30B (+2.5%)
|
67.03B
est: 68.00B (-1.4%)
|
72.35B
est: 72.29B (+0.1%)
|
81.05B
80.63B – 81.48B
+12.1% YoY
|
88.17B
86.29B – 90.05B
+8.8% YoY
|
100.15B
96.89B – 103.40B
+13.6% YoY
|
112.97B
109.89B – 116.05B
+12.8% YoY
|
130.78B
127.21B – 134.34B
+15.8% YoY
|
| EBITDA |
6.83B
est: 9.18B (-25.6%)
|
11.72B
est: 9.05B (+29.5%)
|
13.05B
est: 9.17B (+42.2%)
|
14.64B
est: 11.48B (+27.5%)
|
16.64B
est: 14.17B (+17.4%)
|
15.48B
est: 14.13B (+9.6%)
|
14.68B
est: 12.11B (+21.2%)
|
10.66B
est: 9.35B (+14.0%)
|
6.46B
est: 9.57B (-32.5%)
|
7.93B
est: 10.62B (-25.3%)
|
10.48B
est: 10.01B (+4.7%)
|
11.22B
11.16B – 11.28B
+12.1% YoY
|
12.21B
11.94B – 12.47B
+8.8% YoY
|
13.86B
13.41B – 14.31B
+13.6% YoY
|
15.64B
15.21B – 16.07B
+12.8% YoY
|
18.10B
17.61B – 18.60B
+15.8% YoY
|
| EBIT |
4.02B
est: 6.74B (-40.3%)
|
9.42B
est: 6.65B (+41.7%)
|
10.77B
est: 6.74B (+59.8%)
|
12.15B
est: 8.43B (+44.0%)
|
13.93B
est: 10.41B (+33.8%)
|
12.39B
est: 10.38B (+19.4%)
|
11.44B
est: 8.90B (+28.6%)
|
8.40B
est: 6.87B (+22.3%)
|
3.75B
est: 7.03B (-46.7%)
|
5.23B
est: 7.80B (-32.9%)
|
8.03B
est: 7.01B (+14.6%)
|
7.86B
7.82B – 7.90B
+12.1% YoY
|
8.55B
8.37B – 8.73B
+8.8% YoY
|
9.71B
9.39B – 10.02B
+13.6% YoY
|
10.95B
10.65B – 11.25B
+12.8% YoY
|
12.68B
12.33B – 13.02B
+15.8% YoY
|
| Net Income |
-577.64M
est: 269.81M (-314.1%)
|
3.92B
est: 3.65B (+7.4%)
|
5.76B
est: 4.46B (+29.0%)
|
6.43B
est: 5.33B (+20.6%)
|
5.74B
est: 6.99B (-17.8%)
|
8.98B
est: 6.32B (+42.1%)
|
8.36B
est: 8.06B (+3.7%)
|
4.14B
est: 4.78B (-13.4%)
|
-610.00M
est: 6.58B (-109.3%)
|
771.00M
est: 8.59B (-91.0%)
|
8.39B
est: 5.80B (+44.6%)
|
5.46B
5.28B – 5.65B
-5.9% YoY
|
4.91B
4.68B – 5.14B
-10.1% YoY
|
6.04B
5.68B – 6.40B
+23.0% YoY
|
7.66B
7.39B – 7.93B
+26.8% YoY
|
10.04B
9.69B – 10.40B
+31.1% YoY
|
| SGA |
11.28B
est: 19.69B (-42.7%)
|
11.67B
est: 19.42B (-39.9%)
|
12.79B
est: 19.68B (-35.0%)
|
16.19B
est: 24.63B (-34.3%)
|
20.09B
est: 30.40B (-33.9%)
|
18.84B
est: 30.31B (-37.8%)
|
19.44B
est: 25.99B (-25.2%)
|
20.74B
est: 20.06B (+3.4%)
|
22.15B
est: 20.53B (+7.9%)
|
22.87B
est: 22.78B (+0.4%)
|
23.43B
est: 22.53B (+4.0%)
|
25.26B
25.13B – 25.39B
+12.1% YoY
|
27.48B
26.89B – 28.07B
+8.8% YoY
|
31.21B
30.20B – 32.23B
+13.6% YoY
|
35.21B
34.25B – 36.17B
+12.8% YoY
|
40.76B
39.65B – 41.87B
+15.8% YoY
|
| EPS |
-3.63
est: 1.70 (-313.7%)
|
25.10
est: 22.97 (+9.3%)
|
36.93
est: 28.08 (+31.5%)
|
41.25
est: 33.55 (+22.9%)
|
36.86
est: 44.01 (-16.2%)
|
42.55
est: 39.79 (+6.9%)
|
36.05
est: 50.72 (-28.9%)
|
26.01
est: 30.10 (-13.6%)
|
-3.83
est: 41.40 (-109.3%)
|
4.86
est: 54.10 (-91.0%)
|
52.98
est: 36.53 (+45.0%)
|
34.38
33.21 – 35.54
-5.9% YoY
|
30.90
29.45 – 32.35
-10.1% YoY
|
38.00
35.72 – 40.28
+23.0% YoY
|
48.20
46.49 – 49.91
+26.8% YoY
|
63.20
60.96 – 65.44
+31.1% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-26 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-25 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-22 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
3.15B
OE per share TTM
19.86
Owner's Yield
2.02%
Maintenance CapEx ratio
101.20%
Maint CapEx / Avg PPE
61.6%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 11 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.01% | 191.1K | 0.26% |
| 2 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.01% | 84.7K | 0.48% |
| 3 | Vanguard ESG Global All Cap UCITS ETF (USD) Accumulating V3AA.L | 0.00% | 63.7K | 0.24% |
| 4 | Vanguard ESG Global All Cap UCITS ETF (USD) Distributing V3AL.L | 0.00% | 63.7K | 0.24% |
| 5 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 15.2K | 0.22% |
| 6 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 45.6K | 0.22% |
| 7 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 24.5K | 0.22% |
| 8 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 10.8K | 0.22% |
| 9 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 1.2K | 0.22% |
| 10 | Vanguard Retirement Income ETF Portfolio VRIF.TO | 0.00% | 410.35 | 0.31% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
1.52M
Shares Outstanding
158.39M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Priyavrat Bhartia | MD & Director | 75M | male |
| Arjun Shanker Bhartia | Joint MD & Director | 75M | male |
| Rajagopal Sankaraiah | Advisor | 67M | male |
| Naresh Kapoor | Company Secretary & Compliance Officer | 7M | male |
| Sanjay Gupta | Executive Vice President & Head of Legal | — | male |
| A. Srivastava | Senior Vice President of Corporate Affairs | — | male |
| Shantanu Jha | Group Chief Human Resources Officer | — | male |
| Arun Kumar Sharma | Chief Financial Officer & Group Treasurer | — | male |
| Chandan Singh Sengar | President of Life Science Chemicals | — | male |
| Prakash Chandra Bisht | Executive Vice President of Group Accounts | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for JUBLPHARMA.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
